Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

48.58 +0.05 (+0.10%)
Streaming Delayed Price Updated: 12:40 PM EDT, Apr 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Bristol Myers Delivers Upbeat 2025 Forecast Despite China Tariffs Impact
Bristol Myers reported Q1 revenue of $11.2 billion, raised 2025 guidance, and saw strong Growth Portfolio sales offset Legacy product declines. 
Via Benzinga
Bristol Myers Reports Upbeat Q1 Earnings, Raises Full-Year Guidance: Retail’s Optimistic
The company now expects full-year diluted EPS in the range of $6.70 to $7.00, up from its previous guidance of $6.55 to $6.85. 
Via Stocktwits
Topics World Trade
Exposures Tariff
Bristol Myers Continues A Two-Day Losing Spree Despite Walloping Earnings Estimates
The company recently faced two big clinical trial setbacks that have weighed on shares recently. 
Via Investor's Business Daily
Topics Government
Exposures Political
Bristol-Myers Squibb (NYSE:BMY) Reports Upbeat Q1, Full-Year Outlook Slightly Exceeds Expectations
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, but sales fell by 5.6% year on year to $11.2 billion. The company’s... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Earnings Scheduled For April 24, 2025
Via Benzinga
Bristol Myers Squibb Reports First Quarter Financial Results for 2025
From Bristol Myers Squibb
Via Business Wire
US Stock Futures Drop Amid Mixed Signals From White House On US-China Trade: 'Focus On Quality In A Diversified Manner,' Says Expert
U.S. stock futures fell on Thursday after a two-day advance. Futures of major benchmark indices were lower in premarket. 
Via Benzinga
PepsiCo, Alphabet And 3 Stocks To Watch Heading Into Thursday
Via Benzinga
Dow Jumps Over 400 Points Amid China Tariff Hopes, Investor Fear Eases: Greed Index Remains In 'Fear' Zone
Via Benzinga
Topics Stocks
Exposures US Equities
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Wednesday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
Explore the top gainers and losers within the S&P500 index in today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
What's going on in today's pre-market session: S&P500 movers
Discover the top S&P500 movers in Wednesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Tesla To $303? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Bristol Myers' Cobenfy Falls Short On Primary Endpoint In Phase 3 Schizophrenia Trial, Stock Slides
Bristol Myers' Cobenfy missed its primary endpoint in the Phase 3 ARISE trial but showed symptom improvement in certain subgroups. 
Via Benzinga
Bristol-Myers Squibb (BMY) Reports Earnings Tomorrow: What To Expect
Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be announcing earnings results tomorrow morning. Here’s what investors should know. 
Via StockStory
Bristol Myers Squibb Stock Slides After-Hours As Schizophrenia Trial Misses Goal, But Retail's Buying The Dip
A post-hoc analysis showed more pronounced effects among patients on risperidone compared to those on other antipsychotics, the company said. 
Via Stocktwits
Topics Intellectual Property
Exposures Intellectual Property
Stay updated with the S&P500 stocks that are on the move in today's after-hours session.
After the closing bell on Tuesday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
Beyond The Numbers: 7 Analysts Discuss Bristol-Myers Squibb Stock
Via Benzinga
Bristol Myers Sheds 6% After Promising Schizophrenia Drug Flops In Phase 3 Test
The company spent $14 billion to acquire the developer of this drug, Cobenfy. 
Via Investor's Business Daily
Exposures Product Safety
Bristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Analyst Says FDA Update Is A Win For Camzyos With Simpler Use, Broader Reach
FDA approves Camzyos label update easing echo monitoring and lifting drug interaction limits, supported by 3.5 years of safety data and real-world use 
Via Benzinga
Exposures Product Safety
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
U.S. Food and Drug Administration Updates CAMZYOS® (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
From Bristol Myers Squibb
Via Business Wire
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Trump's New Order Targets Drug Pricing Transparency And Medicare Cost Reduction
Trump orders multi-part executive order to lower drug prices, reduce Medicare costs. Includes guidance on Medicare drug prices, aligning payments with hospital acquisition costs, and investigating... 
Via Benzinga
Topics Government
Exposures Political
Why Is US Pharma Giant Bristol Myers Squibb Stock Trading Lower On Tuesday?
Bristol Myers' Camzyos missed goals in a Phase 3 nHCM trial, showing no significant benefits over placebo but raised no new safety concerns. 
Via Benzinga
Which S&P500 stocks are moving on Tuesday?
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Tuesday as we examine the latest happenings in today's session. 
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks
Curious about the S&P500 stocks that are gapping on Tuesday? Explore the gap up and gap down stocks in the S&P500 index during today's session. 
Via Chartmill
Bristol Myers Slumps On Heart Drug Failure — Taking Cytokinetics With It
The companies are facing off with their heart drugs in a growing disease area. 
Via Investor's Business Daily
Bristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.